#novo-nordisk
#novo-nordisk

6 days ago

Novo Nordisk Roars Back: 6 Catalysts Driving the Pharma's Path to Dominance

Novo Nordisk regained momentum in the GLP-1 market after competition and shortages, driven by strategic wins, resolved shortages, and expanded drug indications, boosting its stock.

#ozempic

Healthcare

Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (Aug 2025)

fromFortune

Healthcare

Novo Nordisk slashes price of Ozempic in half to $499 for cash-paying, eligible U.S. patients

Healthcare

The Creator of Ozempic Is in Terrible Trouble

fromwww.theguardian.com

Healthcare

Sales of Novo Nordisk's diabetes drugs including Ozempic slow sharply

Healthcare

Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (July 2025)

Ozempic's sales are projected to reach $17 billion in 2024, marking its significant success in the weight loss drug market.

Wearables

Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (May 2025)

Ozempic's popularity is transforming Novo Nordisk into a major player in the obesity drug market.

The obesity drug market is expected to grow significantly, reaching $100 billion by 2030.

Healthcare

Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (Aug 2025)

fromFortune

Healthcare

Novo Nordisk slashes price of Ozempic in half to $499 for cash-paying, eligible U.S. patients

Healthcare

The Creator of Ozempic Is in Terrible Trouble

fromwww.theguardian.com

Healthcare

Sales of Novo Nordisk's diabetes drugs including Ozempic slow sharply

Healthcare

Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (July 2025)

Wearables

Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (May 2025)

more#ozempic

The Maker of Ozempic Is in Such Deep Trouble That It's Going on Hiring Lockdown

Despite ushering in the weight-loss injectable craze and reaching a whopping $604 billion market cap in March 2024, Novo has for the past 18 months suffered hit after financial hit as compounding companies cut into its profit margin by selling cheaper, off-brand Ozempic - and as Eli Lilly, the makers of rival jabs Mounjaro and Zepbound, surged ahead thanks to promising news about its orforglipron GLP-1 pill.

Business

Public health

fromInside Higher Ed | Higher Education News, Events and Jobs

Why is GDRX stock up 30% today? GoodRx strikes deal to sell Ozempic and Wegovy after Novo Nordisk's breakup with Hims

GoodRx partners with Novo Nordisk to offer the lowest prices for Ozempic and Wegovy, increasing accessibility for patients.

2 weeks ago

Recipe for Science Superpower? "Pay Your Taxes With Pride"

Denmark's research system fosters successful commercial ventures like Novo Nordisk, illustrating a sustainable model for scientific and economic advancement.

#wegovy

fromwww.aljazeera.com

Healthcare

Wegovy maker Novo Nordisk warns of layoffs as competition grows

Healthcare

Blockbuster weight-loss drug Wegovy is losing market share in the U.S. Here's why

fromBusiness Matters

NYC startup

Novo Nordisk cuts forecasts as Ozempic and Wegovy sales hit by US copycat versions

fromwww.aljazeera.com

Healthcare

Wegovy maker Novo Nordisk warns of layoffs as competition grows

Healthcare

Blockbuster weight-loss drug Wegovy is losing market share in the U.S. Here's why

fromBusiness Matters

NYC startup

Novo Nordisk cuts forecasts as Ozempic and Wegovy sales hit by US copycat versions

more#wegovy

There Is Only 1 GLP-1 Stock to Buy In 2025

Ozempic's approval in 2017 transformed obesity treatment from lifestyle changes to drug-based interventions, utilizing GLP-1 to effectively regulate appetite and manage glucose.

Health

3 Dividend Growth Stocks to Turn $10,000 Into $50,000 by 2035

High dividend growth stocks can potentially deliver triple-digit gains in the long run.

#obesity

Health

The Ozempic boom and new obsession with thinness are threatening body positivity

Social media marketing

Obesity can kill': Controversial campaign by Ozempic drugmaker sparks backlash

Health

The Ozempic boom and new obsession with thinness are threatening body positivity

Social media marketing

Obesity can kill': Controversial campaign by Ozempic drugmaker sparks backlash

more#obesity

7 Killer European Stocks To Buy In July

The article highlights key European stocks, including Spotify and Novo Nordisk, that investors should consider for portfolio growth amid global market uncertainties.

E-Commerce

fromInsideHook

Intellectual property law

Compounding Breaks Up Novo Nordisk-Hims & Hers Partnership

Compounded alternatives to GLP-1 drugs raise safety concerns and regulatory scrutiny.

fromAbove the Law

Patenting Privation (Part III): Empowering Revenge - Above the Law

The FDA's lifting of the shortage declaration has curtailed bulk sales of competing diabetes medications, impacting telehealth revenues significantly.

Startup companies

Novo Nordisk announces CEO transition as share price slips

Novo Nordisk's CEO Lars Fruergaard Jorgensen is stepping down amid market challenges despite leading the company through significant growth in the weight-loss drug sector.

fromwww.aljazeera.com

In surprise move Wegovy-maker Novo Nordisk ousts CEO amid sagging sales

Days earlier, Novo Nordisk cut its sales and profit forecast for the first time since the launch of Wegovy four years ago. Wegovy-maker Novo Nordisk has pushed out CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.

Europe news

fromCbsnews

Novo Nordisk CEO Lars Jorgensen, who led company into weight loss drugs, to step down

Novo Nordisk's board and CEO Lars Fruergaard Jorgensen have agreed his departure is necessary due to recent market challenges and a significant decline in share price.

NYC startup

Startup companies

Novo Nordisk posts strong Q1 as weight-loss revolution claims another victim: WeightWatchers

Novo Nordisk's market outlook improves with FDA's ban on GLP-1 drug copycats.

Despite profit forecasts lowering, investor sentiment towards Novo Nordisk remains optimistic.

NYC startup